:max_bytes(150000):strip_icc()/GettyImages-1393287140-1a0a64aa9b8f4abc85356e41c0f799a2.jpg)
Quick Dispatch:
Your surpass trial tirzepatide SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes – My Endo Consult orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass trial tirzepatide SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes – My Endo Consult ships.
Need Help?
Questions about surpass trial tirzepatide SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes – My Endo Consult, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass trial tirzepatide SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes – My Endo Consult in your area.
SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide
24.10
![Efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1](https://www.researchgate.net/publication/363201315/figure/fig3/AS:11431281082605778@1662084799021/Efficacy-of-tirzepatide-in-phase-2-GPGB-14-and-phase-3-SURPASS-1-to-5-15-19.png)
Efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1
20.72
Tirzepatide Protocol Training as Medical Weight Loss Treatment
26.63
Tirzepatide reduces albuminuria among adults with type 2 diabetes in SURPASS trials
20.29
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
20.06
00188-7/asset/2c20a909-3c0e-4be2-9bc4-c699b73fc56e/main.assets/gr2_lrg.jpg)
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
28.94
The SURPASS 1-5 study as an evaluation of tirzepatide in monotherapy or...
29.25
